Kennis & ervaring
Werkervaring
- 1986-1993: studie geneeskunde (cum laude)
- 1995-2001: opleiding tot kinderarts en promotie onderzoek AMC
- 2001-2003: opleiding tot kinderoncoloog: Koningin Wilhelmina Fonds Fellow
- 2001-2003: diploma Frans kinderoncologie: “DIUOP” (Diplome Interuniversitaires D'Oncologie Pédiatrique
- 2003-2008: algemeen kinderarts Zaans Medisch Centrum.
- 2008-2015: staf kinderoncologie AMC
- 2015- heden: staf kinderoncologie Prinses Máxima Centrum
Promotie
als AGIKO (combinatie promotie en opleiding) 1993-2001.
Overig
1998 Young Investigator Awards: Advances in neuroblastoma research (Bath, England).
2010 AMC: Onderzoek PI
2016: Prinses Máxima Centrum: onderzoek PIPublicaties
- Stutterheim J., Gerritsen A., Zappeij-Kannegieter L., Kleijn I., Dee R., Hooft L., van Noesel M., Bierings M., BertholdF., Versteeg R., Caron H.N., van der Schoot C.e., Tytgat G.A. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. (2008) J Clin Oncol. 26:5443-9. PMID: 18838715
- Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA, van der Schoot CE. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. (2012) Clin Cancer Res. 18:808-14. PMID: 22142825
- Bleeker G, van Eck-Smit BL, Zwinderman KH, Versteeg R, van Noesel MM, Kam BL, Kaspers GJ, van Schie A, Kreissman SG, Yanik G, Hero B, Schmidt M, Laureys G, Lambert B, Ora I, Schulte JH, Caron HN, Tytgat GA. MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. (2014) Eur J Nucl Med Mol Imaging. 42:222-30. PMID:25267348
- van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, Bus E, van Noesel MM, Molenaar JJ, Versteeg R, Fiocco M, Caron HN, van der Schoot CE, Koster J, Tytgat GA. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. (2015) J Mol Diagn. 17:43-52. PMID: 25445214
- Verly IRN, van Kuilenburg ABP, Abeling NGGM, Goorden SMI, Fiocco M, Vaz FM, van Noesel MM, Zwaan CM, Kaspers GJL, Merks JHM, Caron HN, Tytgat GAM. 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. (2018) Eur J Cancer. PMID: 29274926 b102-110.
69041107101